Medistem Laboritories recently announced that it has filed a patent application covering the Angiostem(TM) platform, a technology with potential to benefit cardiac and limb ischemic diseases. Angiostem(TM) is planned to be the company’s first pipeline product intended for US Commercialization.
If approved for human use, the Angiostem(TM) platform will alllow for the manipulation of cord blood so as to enable it to be used by different individuals without the need for immune suppression.
Let us hear your thoughts below: